Age-related diseases account for approximately 70% of all deaths and annually cost the global economy trillions of dollars. BioViva’s patent pending CMV vector delivered genes that increased life spans over 41% in a mouse model. Results were published in the Proceedings of the National Academy of Science (PNAS). Elizabeth Parrish, CEO of BioViva stated, “the proprietary delivery method we are working with is the vector the industry has been waiting for. Its large capacity lets us...